Abstract
Osteoporosis was related with depression especially in patients treated with psychotropic medicine. Selective serotonin reuptake inhibitors (SSRIs), the first-line treatment of depression, could up-regulate the extracellular serotonin (5-HT) levels and affect the serotonin system in bone metabolism. 5-HT transporter(5-HTT) knockout results in bone mass decreased, architecture altered and mechanical properties impaired. Antidepressant-induced osteoporosis has direct and dose-dependent effects. Thus depression patients should evaluate skeletal system and receive antiosteoporotic treatments regularly, particularly during use of SSRI. But some reports have shown a dissociation of Major depressive disorder (MDD) and bone mineral density (BMD). The relationship between depression, BMD and bone metabolism remains elusive. Further studies will be tackled by ‘OMICS’ to understand possible mechanisms and develop new antidepressant for MDD.
Keywords: Bone mineral density, depression, OMICS, osteoporosis, SSRIs.
Current Signal Transduction Therapy
Title:Insight into the Physiopathologic Mechanism for the Coexistence of Depression and Osteoporosis
Volume: 10 Issue: 1
Author(s): Ying Wu, Yi Yang, Haishan Wu, Beibei Zhang, Hui Tang, Jingping Zhao and Jindong Chen
Affiliation:
Keywords: Bone mineral density, depression, OMICS, osteoporosis, SSRIs.
Abstract: Osteoporosis was related with depression especially in patients treated with psychotropic medicine. Selective serotonin reuptake inhibitors (SSRIs), the first-line treatment of depression, could up-regulate the extracellular serotonin (5-HT) levels and affect the serotonin system in bone metabolism. 5-HT transporter(5-HTT) knockout results in bone mass decreased, architecture altered and mechanical properties impaired. Antidepressant-induced osteoporosis has direct and dose-dependent effects. Thus depression patients should evaluate skeletal system and receive antiosteoporotic treatments regularly, particularly during use of SSRI. But some reports have shown a dissociation of Major depressive disorder (MDD) and bone mineral density (BMD). The relationship between depression, BMD and bone metabolism remains elusive. Further studies will be tackled by ‘OMICS’ to understand possible mechanisms and develop new antidepressant for MDD.
Export Options
About this article
Cite this article as:
Wu Ying, Yang Yi, Wu Haishan, Zhang Beibei, Tang Hui, Zhao Jingping and Chen Jindong, Insight into the Physiopathologic Mechanism for the Coexistence of Depression and Osteoporosis, Current Signal Transduction Therapy 2015; 10 (1) . https://dx.doi.org/10.2174/1574362410666150311000100
DOI https://dx.doi.org/10.2174/1574362410666150311000100 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fetal Undernutrition and the Programming of Blood Pressure
Current Nutrition & Food Science Targeting the Cholinergic System for Neuroprotection and/or Enhancement of Functional Recovery Following Neurotrauma
Current Pharmaceutical Design Nur77 Family of Nuclear Hormone Receptors
Current Drug Targets - Inflammation & Allergy Ultra-micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Clinical Importance of Assessment of Type 2 Diabetes Mellitus with Visceral Obesity. A Japanese Perspective
Current Diabetes Reviews Neurochemical Markers in the Mammalian Brain: Structure, Roles in Synaptic Communication, and Pharmacological Relevance
Current Medicinal Chemistry Combining Stress and Dopamine Based Models of Addiction: Towards a Psycho-Neuro-Endocrinological Theory of Addiction
Current Drug Abuse Reviews Neurohormonal Activation in Ischemic Stroke: Effects of Acute Phase Disturbances on Long-Term Mortality
Current Neurovascular Research Using Mass Spectrometry-Based Peptidomics to understand the Brain and Disorders such as Parkinson’s Disease and Schizophrenia
Current Topics in Medicinal Chemistry Melatonin Effects on Plasmodium Life Cycle: New Avenues for Therapeutic Approach
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Hypothalamic Glucose Sensing and Glycaemic Disease
Current Diabetes Reviews The Kynurenine Pathway in the Acute and Chronic Phases of Cerebral Ischemia
Current Pharmaceutical Design Subject Index to Volume 9
Current Pharmaceutical Design Gene Therapy for Neurological Disorders: Challenges and Future Prospects for the Use of Growth Factors for the Treatment of Parkinsons Disease
Current Gene Therapy Disease-Induced Neuroinflammation and Depression
CNS & Neurological Disorders - Drug Targets Serotonin Receptors of Type 6 (5-HT6): What can we Expect from them?
Current Medicinal Chemistry Sympathetic Overactivity in Hypertension and Cardiovascular Disease
Current Vascular Pharmacology Prevention and Treatment of Cardiovascular Disease in Adolescents and Adults through the Transcendental Meditation® Program: A Research Review Update
Current Hypertension Reviews Glucocorticoid Measurements in Health and Disease - Metabolic Implications and the Potential of 24-h Urine Analyses
Mini-Reviews in Medicinal Chemistry Medical Complications in Anorexia and Bulimia Nervosa
Endocrine, Metabolic & Immune Disorders - Drug Targets